Litcius/Paper detail

Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

Bradley J. Monk, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, Michael J. Birrer, Leslie M. Randall, Elena Poddubskaya, Giovanni Scambia, Yaroslav Shparyk, Myong Cheol Lim, Snehalkumar M Bhoola, Joohyuk Sohn, Kan Yonemori, Ross Stewart, Xiaoxi Zhang, Julia Perkins Smith, Carlos Linn, Jonathan A. Ledermann

2021The Lancet Oncology285 citationsDOIOpen Access PDF

Topics & Concepts

AvelumabJavelinMedicineChemotherapyOvarian cancerEpithelial ovarian cancerOncologyInternal medicineOpen labelCancerImmunotherapyClinical trialPembrolizumabEngineeringMechanical engineeringThrowingOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyReproductive Biology and Fertility
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial | Litcius